헬릭스미스

084990KOSDAQ

52.0 / 100

Reference Date: 2026-10-23

Financial Score17.5 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 30.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Helixms is a biotech company established in 1996, specializing in CDMO, clinical CRO, analytical CRO, and H&B (health and beauty) businesses. It operates a state-of-the-art GMP facility compliant with FDA and Korean regulatory standards, and leverages natural-derived material technologies to develop pharmaceuticals and B2B products. The company also focuses on cell and gene therapy production, with extensive experience in global clinical trials and regulatory compliance.

Number of Employees

44people

Average Salary

54.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.27Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-0.33Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.62Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼14.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲47.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 3,885Won52-week high 9,47052-week low 2,805

1-month return6.0Point

1m +30.81% (strong rise)

Volume trend5.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0